Labcorp Holdings Inc.

Labcorp provides contract services across the entire pharmaceutical industry—from early drug discovery to non-clinical and clinical studies, and pharma manufacturing. Through their in-house non-clinical testing platform, the company delivers a broad portfolio of highly specialized evaluation services on a global scale.

Features of Labcorp Holdings Inc.’s Non-clinical Contract Services

Global laboratory network and expert scientific teams

Leveraging an extensive worldwide network of non-clinical laboratories, Labcorp Holdings Inc. provides integrated support for a wide range of drug discovery research activities. Highly experienced scientists and specialists deliver multi-dimensional support, enabling flexible responses to diverse client needs in the preclinical field.

Labcorp Holdings Inc. serves as a reliable development partner for pharmaceutical companies and biotech ventures alike.

End-to-end development support—from early discovery to regulatory submission

Labcorp Holdings Inc. has established a system capable of providing seamless support at every stage of drug development—from the creation of drug candidate compounds to IND/CTA submissions and marketing applications.

Their services cover key components such as DMPK/ADME testing and toxicity evaluations, contributing to efficient and streamlined pharmaceutical development.
This end-to-end capability makes Labcorp Holdings Inc. an ideal partner for companies seeking to outsource comprehensive preclinical programs from the ground up.

Broad testing portfolio with strengths in pharmacokinetics, toxicology, and safety

Labcorp Holdings Inc. offers highly specialized preclinical studies, including DMPK/ADME evaluations, toxicology, safety pharmacology, and reproductive and developmental toxicity (DART). The company maintains robust in vitro and in vivo data acquisition platforms, along with GLP-compliant testing environments.

These capabilities ensure to gain high-precision preclinical data, which is essential for drug discovery.

Example Models Available at Labcorp Holdings Inc.

Rabbit model for DART studies

Labcorp Holdings Inc. conducts reproductive and developmental toxicity studies using rabbit models within DART evaluations to assess prenatal and postnatal toxic effects.

Rabbits are a standard species for teratogenicity studies due to their high sensitivity during fetal development, and they are considered to provide data with strong human correlation.

In compliance with GLP standard, Labcorp Holdings Inc. designs dosing schedules covering the entire gestation period and performs comprehensive assessments of both maternal and fetal parameters, supporting appropriate drug risk evaluation.

Reference:Labcorp Holdings Inc.
https://jp.labcorp.com/biopharma/nonclinical/disciplines/toxicology/dart

Labcorp Holdings Inc. Non-clinical Case Studies

DMPK characterization support for drug candidate compounds

Labcorp provides both in vitro and in vivo DMPK studies to support compound selection in the early stages of drug discovery.

In addition to CYP inhibition studies, protein binding assessments, and permeability/transport evaluations (PAMPA, Caco-2, etc.), Labcorp also conducts PK studies in multiple species, including mouse, rat, dog, and monkey.
Study designs can incorporate considerations such as gastrointestinal absorption and hepatic first-pass metabolism, helping accelerate the evaluation of candidate compounds.

Reference:Labcorp Holdings Inc.（https://jp.labcorp.com/biopharma/nonclinical/disciplines/metabolism）

Company Information